- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 19.06. | CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 16.06. | Potenzial von CMP-002: JPMorgan stuft CAMP4 Therapeutics auf "Overweight" hoch | 10 | Investing.com Deutsch | ||
| CAMP4 THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 16.06. | JPMorgan upgrades CAMP4 Therapeutics stock rating on CMP-002 potential | 2 | Investing.com | ||
| 12.06. | Camp4 Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 10.06. | Chardan initiates CAMP4 Therapeutics stock with buy rating | 2 | Investing.com | ||
| 21.05. | CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 14.05. | Camp4 Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 14.05. | CAMP4 reports positive preclinical seizure data for CMP-002 | 1 | Investing.com | ||
| 14.05. | CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder | 1 | GlobeNewswire (USA) | ||
| 08.05. | Camp4 Therapeutics GAAP EPS of -$0.32 misses by $0.11 | 2 | Seeking Alpha | ||
| 28.04. | CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation | - | GlobeNewswire (USA) | ||
| 17.04. | CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 14.04. | Rodman & Renshaw stuft CAMP4 Therapeutics mit "Buy" ein und sieht 55 % Potenzial | 1 | Investing.com Deutsch | ||
| 14.04. | Rodman & Renshaw initiates CAMP4 Therapeutics stock with buy rating | 2 | Investing.com | ||
| 02.04. | Leerink raises CAMP4 Therapeutics price target on CMP-002 progress | 1 | Investing.com | ||
| 02.04. | Fortschritte bei CMP-002: Leerink erhöht Kursziel für CAMP4 Therapeutics | 4 | Investing.com Deutsch | ||
| 24.03. | CAMP4 verstärkt Verwaltungsrat mit Finanzexperte Michael MacLean | 3 | Investing.com Deutsch | ||
| 24.03. | CAMP4 Therapeutics appoints Michael MacLean to board of directors | 2 | Investing.com | ||
| 24.03. | CAMP4 Therapeutics: CAMP4 Appoints Michael MacLean to its Board of Directors | 1 | GlobeNewswire (USA) |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CLINUVEL | 6,190 | +1,04 % | CLINUVEL PHARMACEUTICALS LIMITED: SCENESSE approved for EPP in Canada | ||
| EDITAS MEDICINE | 2,580 | +2,79 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,102 | +2,04 % | CARDIOL THERAPEUTICS INC ruhig im strategischen Fokus | ||
| CELLECTAR BIOSCIENCES | 2,540 | +1,20 % | Cellectar publishes phase 1 data on multiple myeloma treatment | ||
| CYTODYN | 0,198 | 0,00 % | CytoDyn Inc.: CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer's Disease | Phase 2a study will evaluate the safety and biological activity of leronlimab in patients over the age of 50 with early-stage, biomarker-confirmed Alzheimer's disease VANCOUVER, Washington, June 11... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 0,789 | +3,68 % | CARDIFF ONCOLOGY INC im strukturellen Gleichgewicht | ||
| EMERGENT BIOSOLUTIONS | 6,670 | -0,74 % | Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)] to Support U.S. Biodefense Strategy | GAITHERSBURG, Md., May 28, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has been awarded a contract modification valued at approximately $64.5 million from the... ► Artikel lesen | |
| DENALI THERAPEUTICS | 19,670 | -1,06 % | Will Recent Setbacks Impact Growth Prospects of DNLI Stock? | ||
| CEL-SCI | 1,000 | 0,00 % | CEL-SCI launches confirmatory study for head and neck cancer drug | ||
| CYTOKINETICS | 68,32 | -2,76 % | Wall Street Analysts Think Cytokinetics (CYTK) Could Surge 30.54%: Read This Before Placing a Bet | ||
| COHERUS ONCOLOGY | 1,220 | +1,41 % | Coherus Oncology, Inc.: Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI (toripalimab-tpzi) | REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS) and Zumutor Biologics Inc. ("Zumutor"), an immuno-oncology biotech company, today announced a clinical... ► Artikel lesen | |
| CURIS | 4,220 | +7,38 % | XFRA CUS1: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 3,240 | +1,12 % | CytomX Therapeutics Inc.: CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer | - Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX's PROBODY- and Regeneron's Veloci-Bi- platforms - - CytomX to receive... ► Artikel lesen | |
| FATE THERAPEUTICS | 2,328 | -2,27 % | H.C. Wainwright reiterates Fate Therapeutics stock rating at buy | ||
| FAETH THERAPEUTICS | 25,660 | -1,08 % | Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer | - Stockholders approved conversion of the Series B preferred stock issued in the February 2026 acquisition of Faeth Therapeutics and concurrent private placement -
- Company changed name to Faeth... ► Artikel lesen |
Das Unternehmen CAMP4 THERAPEUTICS CORP kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,200 (-5,13 %) liegt der Kurs bei 3,700 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CAMP4 THERAPEUTICS CORP finden Sie auf Wallstreet Online.